Dr. Mangano’s study
The study, to determine the risk of Trasylol renal failure and other adverse side effects of Trasylol, was conducted by Dr. Dennis T. Mangano, in an effort to unveil longstanding safety concerns regarding the drug.

In comparison with those who took generic medications and no medications at all, the risk for Trasylol kidney failure in patients taking the medication was nearly doubled.

Renal failure from Trasylol
Renal failure is characterized by the body’s inability to filter waste and fluids, leaving hazardous levels of excess. Trasylol renal failure can occur after any cardiovascular procedure in which Trasylol is administered and in which the blood vessels or kidneys are blocked.

Symptoms of Trasylol renal failure may include bleeding of the stomach or intestines, fluid retention, confusion, seizures, and in severe cases, comas.

Trasylol renal failure is a serious and potentially life-threatening condition which, in severe cases, must be treated by dialysis. Dialysis operates as an artificial means of removing waste and excess fluid from the blood when the kidneys are compromised.

Trasylol side effects
In addition to Trasylol renal failure, the medication displayed a number of other serious and significantly heightened risk factors. The risk for heart attack associated with the use of Trasylol is increased by approximately 50%.

The risk of heart failure is increased by 109%, and the risk of enduring a stroke caused by Trasylol is over 180% greater in comparison with other blood clotting medications.

Alternatives
The findings of Dr. Mangano’s research strongly support the use of alternate medications for the prevention of Trasylol renal failure. Generic medications such as aminocaproic acid and tranexamic acid have proven to be just as effective, more economical and substantially less dangerous options for patients undergoing cardiovascular surgery.

Dr. Mangano has commented on his study, “In good conscience, I could not administer Trasylol to this group of patients, especially given the availability of safer alternatives.”